This is an uncontrolled, open-label, Phase III trial of peginterferon alfa-2a (Pegasys) in
participants coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV).
Participants with HIV/HCV who do not show negative or reduced HCV ribonucleic acid (RNA)
after at least 12 weeks of treatment with peginterferon alfa-2a plus ribavirin will receive a
low dose of peginterferon alfa-2a for 18 months. The primary objective is to evaluate safety
and tolerability. Secondary objectives are to evaluate histological, virological, and
biochemical effects.